Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Transplanted epithelial stem cells from a healthy eye repaired irreversible corneal injury and restored at least partial ...

Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.

Seattle's Nautilus Biotechnology is laying off 16% of workforce, and plans to release its commercial platform in late 2026.

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

David Furnish’s leadership at EJAF proves brands can do more than raise awareness —they can dismantle stigma and drive ...

Salesforce is expected to report fourth-quarter results after the market closes Wednesday, with analysts largely bullish on ...

Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...

Salesforce (CRM) reported fiscal fourth-quarter earnings and offered an outlook that fell short of analysts' expectations, ...

Investors eyeing high-growth stocks should consider Corcept Therapeutics, TKO Group, and others with strong earnings ...

Eli Lilly and Company, UnitedHealth Group, AbbVie, Walmart, Johnson & Johnson, Natera, and Gilead Sciences are the seven Medical stocks to watch today, according to MarketBeat’s stock screener tool.